Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 197

1.

Optimising bortezomib in newly diagnosed multiple myeloma.

Rajkumar SV.

Lancet Oncol. 2010 Oct;11(10):909-10. doi: 10.1016/S1470-2045(10)70199-6. Epub 2010 Aug 23. No abstract available.

PMID:
20739219
2.

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.

Mateos MV, Oriol A, Martínez-López J, Gutiérrez N, Teruel AI, de Paz R, García-Laraña J, Bengoechea E, Martín A, Mediavilla JD, Palomera L, de Arriba F, González Y, Hernández JM, Sureda A, Bello JL, Bargay J, Peñalver FJ, Ribera JM, Martín-Mateos ML, García-Sanz R, Cibeira MT, Ramos ML, Vidriales MB, Paiva B, Montalbán MA, Lahuerta JJ, Bladé J, Miguel JF.

Lancet Oncol. 2010 Oct;11(10):934-41. doi: 10.1016/S1470-2045(10)70187-X. Epub 2010 Aug 23.

PMID:
20739218
3.

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.

Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Morabito F, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Ciccone G, Boccadoro M.

J Clin Oncol. 2010 Dec 1;28(34):5101-9. doi: 10.1200/JCO.2010.29.8216. Epub 2010 Oct 12.

PMID:
20940200
4.

Bortezomib plus melphalan and prednisone for multiple myeloma.

Avvisati G.

N Engl J Med. 2008 Dec 11;359(24):2613; author reply 2613-4. No abstract available.

PMID:
19090032
5.

Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates.

Kristinsson SY, Landgren O, Rajkumar VS.

Cancer J. 2009 Nov-Dec;15(6):473-8. doi: 10.1097/PPO.0b013e3181c60f08. Review.

6.

Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.

Morabito F, Gentile M, Mazzone C, Rossi D, Di Raimondo F, Bringhen S, Ria R, Offidani M, Patriarca F, Nozzoli C, Petrucci MT, Benevolo G, Vincelli I, Guglielmelli T, Grasso M, Marasca R, Baldini L, Montefusco V, Musto P, Cascavilla N, Majolino I, Musolino C, Cavo M, Boccadoro M, Palumbo A.

Blood. 2011 Nov 24;118(22):5759-66. doi: 10.1182/blood-2011-05-353995. Epub 2011 Sep 27.

7.

Update on recent developments for patients with newly diagnosed multiple myeloma.

Palumbo A, Magarotto V, Gay F, Falco P, Bringhen S, Boccadoro M.

Ann N Y Acad Sci. 2008 Sep;1138:19-21. doi: 10.1196/annals.1414.004.

PMID:
18837878
8.

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.

Palumbo A, Bringhen S, Larocca A, Rossi D, Di Raimondo F, Magarotto V, Patriarca F, Levi A, Benevolo G, Vincelli ID, Grasso M, Franceschini L, Gottardi D, Zambello R, Montefusco V, Falcone AP, Omedé P, Marasca R, Morabito F, Mina R, Guglielmelli T, Nozzoli C, Passera R, Gaidano G, Offidani M, Ria R, Petrucci MT, Musto P, Boccadoro M, Cavo M.

J Clin Oncol. 2014 Mar 1;32(7):634-40. doi: 10.1200/JCO.2013.52.0023. Epub 2014 Jan 21.

PMID:
24449241
9.

Bortezomib plus melphalan and prednisone for multiple myeloma.

Islam A, Ambrus JL.

N Engl J Med. 2008 Dec 11;359(24):2613; author reply 2613-4. doi: 10.1056/NEJMc086420. No abstract available.

10.

Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.

Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, Cottler-Fox M, Mohiuddin A, Alsayed Y, Tricot G, Bolejack V, Zangari M, Epstein J, Petty N, Steward D, Jenkins B, Gurley J, Sullivan E, Crowley J, Shaughnessy JD Jr.

Br J Haematol. 2007 Jul;138(2):176-85.

PMID:
17593024
11.

Bortezomib plus melphalan and prednisone for multiple myeloma.

Tsubokura M, Kami M, Komatsu T.

N Engl J Med. 2008 Dec 11;359(24):2613; author reply 2613-4. No abstract available.

PMID:
19090031
12.

Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.

Morabito F, Bringhen S, Larocca A, Wijermans P, Victoria Mateos M, Gimsing P, Mazzone C, Gottardi D, Omedè P, Zweegman S, José Lahuerta J, Zambello R, Musto P, Magarotto V, Schaafsma M, Oriol A, Juliusson G, Cerrato C, Catalano L, Gentile M, Isabel Turel A, Marina Liberati A, Cavalli M, Rossi D, Passera R, Rosso S, Beksac M, Cavo M, Waage A, San Miguel J, Boccadoro M, Sonneveld P, Palumbo A, Offidani M.

Am J Hematol. 2014 Apr;89(4):355-62. doi: 10.1002/ajh.23641. Epub 2014 Feb 5.

13.

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.

Palumbo A, Gay F, Falco P, Crippa C, Montefusco V, Patriarca F, Rossini F, Caltagirone S, Benevolo G, Pescosta N, Guglielmelli T, Bringhen S, Offidani M, Giuliani N, Petrucci MT, Musto P, Liberati AM, Rossi G, Corradini P, Boccadoro M.

J Clin Oncol. 2010 Feb 10;28(5):800-7. doi: 10.1200/JCO.2009.22.7561. Epub 2010 Jan 4. Erratum in: J Clin Oncol. 2010 May 1;28(13):2314.

PMID:
20048187
14.

First-line treatment of elderly multiple myeloma patients.

Palumbo A.

Clin Adv Hematol Oncol. 2010 Aug;8(8):529-30. No abstract available.

PMID:
20966887
15.

"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.

Gasparetto C, Gockerman JP, Diehl LF, de Castro CM, Moore JO, Long GD, Horwitz ME, Keogh G, Chute JP, Sullivan KM, Neuwirth R, Davis PH, Sutton LM, Anderson RD, Chao NJ, Rizzieri D.

Biol Blood Marrow Transplant. 2010 Jan;16(1):70-7. doi: 10.1016/j.bbmt.2009.08.017. Epub 2009 Sep 3.

16.

Cutaneous involvement in multiple myeloma and bortezomib.

Siniscalchi A, Fratoni S, Santeusanio G, Del Poeta G, de Fabritiis P, Caravita T.

Ann Hematol. 2009 Nov;88(11):1137-9. doi: 10.1007/s00277-009-0717-7. Epub 2009 Mar 4. No abstract available.

PMID:
19259673
17.

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.

Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Esseltine DL, Liu K, Cakana A, van de Velde H, San Miguel JF.

J Clin Oncol. 2010 May 1;28(13):2259-66. doi: 10.1200/JCO.2009.26.0638. Epub 2010 Apr 5.

PMID:
20368561
18.

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG; VISTA Trial Investigators..

N Engl J Med. 2008 Aug 28;359(9):906-17. doi: 10.1056/NEJMoa0801479.

19.

Hematology: Bortezomib in newly diagnosed multiple myeloma.

Berenson JR.

Nat Rev Clin Oncol. 2009 May;6(5):255-6. doi: 10.1038/nrclinonc.2009.47.

PMID:
19390550
20.

[Complications and managements in treatment of melphalan, prednisone and new agents].

Ishida T.

Nihon Rinsho. 2015 Feb;73 Suppl 2:649-52. Japanese. No abstract available.

PMID:
25831841

Supplemental Content

Support Center